Invitrogen Launches Vector NTI(R) Advance(TM) 10; Release Includes Vector NTI(R) Open Access Policy and Vector NTI(R) User Community to Drive Life Science Standardization
Invitrogen Corporation, a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, today announced the release of its latest technology and eScience contribution to the life sciences, Vector NTI Advance(TM) 10. Centering on its award-winning Vector NTI(R) sequence analysis software, Vector NTI Advance(TM) 10 is the latest Windows(R) version of this application.
To coincide with the release, Invitrogen is also launching the Vector NTI(R) Open Access policy and the online Vector NTI(R) User Community. The Open Access policy allows researchers in not-for-profit laboratories to obtain their own annual, renewable licenses of Vector NTI(R) at no cost. The Vector NTI(R) User Community is designed to be the online meeting place for researchers to acquire the latest versions of the software, obtain technical resources, and ultimately communicate with Invitrogen and other users on all aspects of the software and its uses.
“The launch of Vector NTI Advance(TM) 10 and the creation of a Vector NTI(R) Open Access policy continues our commitment to making our technologies more powerful and more accessible to researchers in all areas of life science,” said Gregory T. Lucier, Chairman and CEO of Invitrogen. “We recognize the need researchers have for access to the best possible tools to drive research forward. We also believe in the importance of having standards in the life sciences industry, and Vector NTI software is capable of performing that role. We look forward to having tens of thousands of users in the academic, government and research institutions take advantage of our Open Access policy.”
Two major research institutions have reviewed the Open Access policy and have utilized Vector NTI(R) software across their campuses. The Wellcome Trust Sanger Institute, a world-renowned genome center best known for its major contributions to the Human Genome Project, understands the importance of researchers having access to state-of-the art bioinformatics tools, as well as the need for standard applications and analyses. All the basic sequence data and all software tools developed at the Institute are released freely into the public domain.
“We use a wide range of different software for different informatics needs and Vector NTI(R) is a very powerful suite of DNA and protein sequence analysis tools,” said Dr. Gareth Maslen, Informatics Project Manager at the Sanger Institute. “The Open Access Policy allows us to receive free, annual licenses for our Vector NTI(R) software, and we envisage this will simplify deployment of the software and improve access for our researchers.”
Invitrogen has also been working with The Scripps Research Institute. Vector NTI(R) desktop software is now available to all researchers at the Scripps Florida campus.
“We appreciate the Open Access policy because The Scripps Research Institute is committed to supporting efforts that provide greater access to the tools and data that are crucial to helping life science researchers understand biology,” says Dr. Nick Tsinoremas, Director of Informatics at Scripps Florida. “The benefits to the scientific community of Invitrogen’s drive for standardization are clear, not only can students and post-docs conduct their research using the latest software, but they are also better prepared for the academic, pharmaceutical and biotechnology jobs of tomorrow. The fact that Vector NTI(R) software imports, handles and exports data in all the key public sequence file formats means that sharing data among groups of researchers is easier than ever.”
Information on Vector NTI Advance(TM) 10, Vector NTI(R) Open Access policy and the online Vector NTI(R) User Community is available at www.invitrogen.com/VectorNTICommunity .
About Invitrogen
Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology — placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information, visit www.invitrogen.com .
